Abstract
Addition of high-dose chemotherapy (HDCT) to standard first-line treatment does not improve treatment response in patients with intermediate-risk or poor-risk metastatic germ cell tumours (GCT), according to results from a US multicentre randomised phase III study (J Clin Oncol 2007; 25: 247–56).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
